Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
MM&M13d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
CagriSema was found to achieve an average weight loss of 22.7% in patients over 68 weeks. These results sent the pharma giant’s shares tumbling, as it missed Novo’s expected target of 25% weight loss.
Hosted on MSN1mon
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote ... in a mid-stage study. Unlike CagriSema, which delivered 22.7% weight loss over 68 weeks, AMGN’s MariTide achieved an ...
Benzinga.com1mon
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development. Viking Therapeutics highlighted new clinical data from its ...